C.H.-based drug firm Cempra launches Phase 3 trial
Chapel Hill, N.C. —
The Phase 3 trial is for its antibiotic called solithromycin. It will be tested on patients with community-acquired bacterial pneumonia.
"Physicians need safe, convenient and active antibiotics to treat CABP, a disease that is the number one cause of death due to infection," said Prabhavathi Fernandes, chief executive officer of Cempra. "Current therapy for moderate to moderately-severe CABP is a choice between combination therapy with intravenous antibiotics or oral administration of fluoroquinolone antibiotics. The former involves intravenous therapy, possibly requiring hospital admission and the latter has been associated with significant side effects, possibly including Clostridium difficile infection due to the class's broad activity spectrum."
Log in or upgrade to view WRALTechWire Insider content
Please Log In to add a comment.
Best of TechWire Insider
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle
- ChannelAdvisor seeks $80M, sets share target price for IPO
- IT job openings 28% below 2012 numbers, report shows